View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsChemoCentryx 향후 성장Future 기준 점검 5/6핵심 정보69.1%이익 성장률91.90%EPS 성장률Biotechs 이익 성장22.9%매출 성장률85.1%향후 자기자본이익률6.59%애널리스트 커버리지Low마지막 업데이트n/a최근 향후 성장 업데이트Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 8 analysts covering ChemoCentryx expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$157.3m in 2024. Average annual earnings growth of 57% is required to achieve expected profit on schedule.모든 업데이트 보기Recent updatesReported Earnings • Aug 09Second quarter 2022 earnings released: US$0.44 loss per share (vs US$0.56 loss in 2Q 2021)Second quarter 2022 results: US$0.44 loss per share (up from US$0.56 loss in 2Q 2021). Revenue: US$11.8m (up US$9.95m from 2Q 2021). Net loss: US$31.7m (loss narrowed 19% from 2Q 2021). Over the next year, revenue is forecast to grow 264%, compared to a 24% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has increased by 102% per year, which means it is well ahead of earnings.Reported Earnings • May 06First quarter 2022 earnings released: US$0.55 loss per share (vs US$0.43 loss in 1Q 2021)First quarter 2022 results: US$0.55 loss per share (down from US$0.43 loss in 1Q 2021). Revenue: US$5.46m (down 47% from 1Q 2021). Net loss: US$38.6m (loss widened 30% from 1Q 2021). Over the next year, revenue is forecast to grow 317%, compared to a 28% growth forecast for the industry in Germany.Board Change • Apr 27Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 4 highly experienced directors. Executive VP, Chief Financial & Administrative Officer, Secretary and Director Susan Kanaya was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Apr 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 4 highly experienced directors. Executive VP, Chief Financial & Administrative Officer, Secretary and Director Susan Kanaya was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Mar 03Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: US$1.89 loss per share (down from US$0.84 loss in FY 2020). Revenue: US$32.2m (down 50% from FY 2020). Net loss: US$131.8m (loss widened 138% from FY 2020). Revenue missed analyst estimates by 4.3%. Over the next year, revenue is forecast to grow 189%, compared to a 64% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has increased by 44% per year, which means it is well ahead of earnings.Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 8 analysts covering ChemoCentryx expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$157.3m in 2024. Average annual earnings growth of 57% is required to achieve expected profit on schedule.Reported Earnings • Nov 10Third quarter 2021 earnings released: US$0.32 loss per share (vs US$0.35 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$17.7m (up 249% from 3Q 2020). Net loss: US$22.3m (loss narrowed 7.3% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has increased by 62% per year, which means it is well ahead of earnings.Reported Earnings • Aug 11Second quarter 2021 earnings released: US$0.56 loss per share (vs US$0.32 profit in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2021 results: Revenue: US$1.81m (down 96% from 2Q 2020). Net loss: US$39.2m (down 294% from profit in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.Recent Insider Transactions • May 11Executive VP & COO recently bought €99k worth of stockOn the 7th of May, Tausif Butt bought around 11k shares on-market at roughly €9.10 per share. This was the largest purchase by an insider in the last 3 months. This was Tausif's only on-market trade for the last 12 months.Reported Earnings • May 02First quarter 2021 earnings released: US$0.43 loss per share (vs US$0.35 loss in 1Q 2020)The company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: US$10.4m (up 72% from 1Q 2020). Net loss: US$29.7m (loss widened 37% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has increased by 59% per year, which means it is well ahead of earnings.Recent Insider Transactions • Mar 13Director recently sold €1.5m worth of stockOn the 5th of March, Geoffrey Parker sold around 32k shares on-market at roughly €47.52 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €4.8m more than they bought in the last 12 months.Reported Earnings • Mar 02Full year 2020 earnings released: US$0.84 loss per share (vs US$0.97 loss in FY 2019)The company reported a solid full year result with improved revenues and control over costs, although losses were not reduced. Full year 2020 results: Revenue: US$64.9m (up 80% from FY 2019). Net loss: US$55.4m (flat on FY 2019). Over the last 3 years on average, earnings per share has fallen by 65% per year but the company’s share price has increased by 86% per year, which means it is well ahead of earnings.Analyst Estimate Surprise Post Earnings • Mar 02Revenue misses expectationsRevenue missed analyst estimates by 5.6%. Over the next year, revenue is expected to shrink by 19% compared to a 55% growth forecast for the Biotechs industry in Germany.Is New 90 Day High Low • Feb 06New 90-day high: €54.18The company is up 20% from its price of €45.32 on 06 November 2020. The German market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €86.28 per share.Recent Insider Transactions • Feb 05Independent Director recently sold €1.0m worth of stockOn the 2nd of February, Thomas Edwards sold around 20k shares on-market at roughly €50.67 per share. In the last 3 months, they made an even bigger sale worth €1.3m. Insiders have been net sellers, collectively disposing of €3.3m more than they bought in the last 12 months.Recent Insider Transactions • Dec 30Independent Director recently sold €1.3m worth of stockOn the 28th of December, Thomas Edwards sold around 25k shares on-market at roughly €50.19 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €2.3m more than they bought in the last 12 months.Is New 90 Day High Low • Dec 15New 90-day high: €49.12The company is up 12% from its price of €43.92 on 16 September 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €76.07 per share.Is New 90 Day High Low • Dec 10New 90-day high: €47.85The company is up 12% from its price of €42.71 on 03 September 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €70.28 per share.Is New 90 Day High Low • Nov 20New 90-day high: €47.06The company is up 4.0% from its price of €45.15 on 21 August 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €68.44 per share.Reported Earnings • Nov 11Third quarter 2020 earnings released: US$0.35 loss per shareThe company reported a poor third quarter result with increased losses and weaker revenues and control over expenses. Third quarter 2020 results: Revenue: US$5.09m (down 52% from 3Q 2019). Net loss: US$24.1m (loss widened 87% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has increased by 96% per year, which means it is well ahead of earnings.Analyst Estimate Surprise Post Earnings • Nov 11Revenue misses expectationsRevenue missed analyst estimates by 53%. Over the next year, revenue is expected to shrink by 6.9% compared to a 309% growth forecast for the Biotechs industry in Germany.공시 • Oct 29ChemoCentryx, Inc. Announces Positive Topline Results of Phase II Aurora Clinical Trial of Avacopan in the Treatment of Hidradenitis Suppurativa (HS)ChemoCentryx, Inc. announced positive topline data from the company’s AURORA randomized, double-blind, placebo-controlled, multi-center Phase II clinical trial of avacopan for the treatment of the chronic disabling skin disease Hidradenitis Suppurativa (HS). Avacopan is a first-in-class, orally-administered selective inhibitor of the complement C5a receptor. The Phase II AURORA clinical trial randomized 398 patients to one of three treatment arms. The study population included patients with moderate HS (Hurley Stage II) or severe HS (Hurley Stage III), which were stratified evenly across the treatment groups. The primary endpoint of the proportion of all patients (both moderate Hurley Stage II plus severe Hurley Stage III) achieving Hidradenitis Suppurativa Clinical Response (HiSCR), as assessed 10 mg twice-daily (BID) and 30 mg BID dosing regimens of avacopan against placebo after 12 weeks of treatment in the combined study population, was not achieved with statistical significance at either dose level, although a numerical improvement was noted at the 30mg BID dose. Importantly, avacopan 30mg BID demonstrated a statistically significant higher response than placebo in the pre-specified population of Hurley Stage III (severe) HS patients in the study. The Company plans to advance avacopan into Phase III development for the treatment of severe HS. A consistency of effect with avacopan was noted in Hurley Stage III patients across every secondary endpoint assessed to date. Favorable reductions for avacopan were observed in International HS Severity Score (IHS4), as well as reduction in AN (abscesses and inflammatory nodules), draining fistula, and abscess count at week 12 (all % change from baseline to week 12), relative to placebo. Avacopan demonstrated a favorable safety profile. Treatment emergent adverse events (TEAEs) of all types were observed to be fewer in the avacopan groups (48.5%) than with placebo (55%). The majority of TEAEs were related to underlying HS and were mild to moderate. Serious TEAEs were observed in 2.3% of placebo patients vs. 1.5% on avacopan.공시 • Sep 18ChemoCentryx, Inc. Announces FDA Acceptance of the Avacopan New Drug Application for the Treatment of ANCA-Associated VasculitisChemoCentryx, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for avacopan, an orally-administered selective complement 5a receptor inhibitor, for the treatment of ANCA-Associated Vasculitis and has set July 7, 2021 as the Prescription Drug User Fee Act (PDUFA) goal date for the avacopan NDA. Avacopan is a first-in-class, orally administered therapy that employs a novel, highly targeted mode of action in the treatment of ANCA-associated vasculitis. In its NDA acceptance letter, the FDA also indicated that it may, but has not yet determined whether to hold an advisory committee meeting to discuss the application per guidelines for new molecular entities. The NDA included data from the global, Phase III ADVOCATE trial, which demonstrated statistical superiority in sustaining remission at 52 weeks in the avacopan group compared to the prednisone group. In the trial, the avacopan group also showed significantly lower glucocorticoid toxicity, greater improvement in kidney function and greater improvement in health-related quality of life measures compared to the prednisone group. Finally, avacopan demonstrated favorable safety results, with fewer patients having serious adverse events in the avacopan group than in the prednisone group. ADVOCATE and ANCA-Associated Vasculitis: The ADVOCATE trial of avacopan was a global, randomized, double-blind, active-controlled, double-dummy Phase III trial of 331 patients with ANCA-associated vasculitis in 20 countries. Eligible study subjects were randomized to receive avacopan plus either rituximab or cyclophosphamide (followed by azathioprine/mycophenolate) or prednisone plus either rituximab or cyclophosphamide (followed by azathioprine/mycophenolate). ANCA-associated vasculitis is a systemic disease in which over-activation of the complement pathway further activates neutrophils, leading to inflammation and destruction of small blood vessels. This results in organ damage and failure, with the kidney as the major target, and is fatal if not treated. Currently, treatment for ANCA-associated vasculitis consists of courses of non-specific immuno-suppressants (cyclophosphamide or rituximab), combined with the administration of daily glucocorticoids (steroids) for prolonged periods of time, which can be associated with significant clinical risk including death from infection. Avacopan is a first-in-class, orally-administered small molecule that employs a novel, highly targeted mode of action in the treatment of ANCA-associated vasculitis and other complement-driven autoimmune and inflammatory diseases. By precisely blocking the receptor (the C5aR) for the pro-inflammatory complement system fragment known as C5a on destructive inflammatory cells such as blood neutrophils, avacopan arrests the ability of those cells to do damage in response to C5a activation, which is known to be the driver of ANCA-associated vasculitis. Current therapies for ANCA-associated vasculitis and other related illnesses typically include broad immunosuppression with daily doses of glucocorticoids (steroids) such as prednisone or methylprednisone, which can cause significant illness and even death. Avacopan therapy was designed to prevent these outcomes. Moreover, avacopan’s selective inhibition of only the C5aR leaves the beneficial C5a pathway through the C5L2 receptor functioning normally. ChemoCentryx is also developing avacopan for the treatment of patients with C3 glomerulopathy (C3G) and hidradenitis suppurativa (HS). The U.S. Food and Drug Administration has granted avacopan orphan drug designation for ANCA-associated vasculitis and C3G. The European Commission has granted orphan medicinal product designation for avacopan for the treatment of two forms of ANCA-associated vasculitis: microscopic polyangiitis and granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis), as well as for C3G. ChemoCentryx is responsible for the discovery and development of avacopan and owns and retains the commercial rights to the drug in the United States. ChemoCentryx's Kidney Health Alliance with Vifor Pharma provides Vifor Pharma with exclusive rights to commercialize avacopan in markets outside of the U.S.공시 • Aug 04ChemoCentryx, Inc. to Report Q2, 2020 Results on Aug 10, 2020ChemoCentryx, Inc. announced that they will report Q2, 2020 results at 5:00 PM, Eastern Standard Time on Aug 10, 2020공시 • Jul 03ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from Russell Microcap IndexChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from Russell Microcap Index이익 및 매출 성장 예측DB:2CX - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202441968-6116112/31/2023190-55-25-12212/31/202264-140-94-5226/30/202237-133-59-53N/A3/31/202227-141-54-45N/A12/31/202132-132-95-76N/A9/30/202134-121-112-84N/A6/30/202122-123-102-75N/A3/31/202169-63-101-75N/A12/31/202065-55-97-81N/A9/30/202071-41-89-82N/A6/30/202076-30-85-83N/A3/31/202034-65-81-79N/A12/31/201936-55-71-70N/A9/30/201935-51-66-65N/A6/30/201934-49-66-66N/A3/31/201942-40-44-43N/A12/31/201843-381616N/A9/30/201890123638N/A6/30/201890174142N/A3/31/201884141920N/A12/31/2017821845N/A9/30/201731-29-10-10N/A6/30/201726-30-5-5N/A3/31/201720-317676N/A12/31/201612-403939N/A9/30/20167-443839N/A6/30/20163-483838N/A3/31/2016N/A-51N/A-41N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 2CX 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(0.03%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: 2CX (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: 2CX 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: 2CX 의 수익(연간 85.1%)이 German 시장(연간 6.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 2CX 의 수익(연간 85.1%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 2CX의 자본 수익률은 3년 후 6.6%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2022/10/23 10:41종가2022/10/19 00:00수익2022/06/30연간 수익2021/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스ChemoCentryx, Inc.는 15명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Madhu KumarB. Riley Securities, Inc.Harshita PolishettyB. Riley Securities, Inc.Dae Gon HaBTIG12명의 분석가 더 보기
Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 8 analysts covering ChemoCentryx expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$157.3m in 2024. Average annual earnings growth of 57% is required to achieve expected profit on schedule.
Reported Earnings • Aug 09Second quarter 2022 earnings released: US$0.44 loss per share (vs US$0.56 loss in 2Q 2021)Second quarter 2022 results: US$0.44 loss per share (up from US$0.56 loss in 2Q 2021). Revenue: US$11.8m (up US$9.95m from 2Q 2021). Net loss: US$31.7m (loss narrowed 19% from 2Q 2021). Over the next year, revenue is forecast to grow 264%, compared to a 24% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has increased by 102% per year, which means it is well ahead of earnings.
Reported Earnings • May 06First quarter 2022 earnings released: US$0.55 loss per share (vs US$0.43 loss in 1Q 2021)First quarter 2022 results: US$0.55 loss per share (down from US$0.43 loss in 1Q 2021). Revenue: US$5.46m (down 47% from 1Q 2021). Net loss: US$38.6m (loss widened 30% from 1Q 2021). Over the next year, revenue is forecast to grow 317%, compared to a 28% growth forecast for the industry in Germany.
Board Change • Apr 27Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 4 highly experienced directors. Executive VP, Chief Financial & Administrative Officer, Secretary and Director Susan Kanaya was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Apr 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 4 highly experienced directors. Executive VP, Chief Financial & Administrative Officer, Secretary and Director Susan Kanaya was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Mar 03Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: US$1.89 loss per share (down from US$0.84 loss in FY 2020). Revenue: US$32.2m (down 50% from FY 2020). Net loss: US$131.8m (loss widened 138% from FY 2020). Revenue missed analyst estimates by 4.3%. Over the next year, revenue is forecast to grow 189%, compared to a 64% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has increased by 44% per year, which means it is well ahead of earnings.
Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 8 analysts covering ChemoCentryx expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$157.3m in 2024. Average annual earnings growth of 57% is required to achieve expected profit on schedule.
Reported Earnings • Nov 10Third quarter 2021 earnings released: US$0.32 loss per share (vs US$0.35 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$17.7m (up 249% from 3Q 2020). Net loss: US$22.3m (loss narrowed 7.3% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has increased by 62% per year, which means it is well ahead of earnings.
Reported Earnings • Aug 11Second quarter 2021 earnings released: US$0.56 loss per share (vs US$0.32 profit in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2021 results: Revenue: US$1.81m (down 96% from 2Q 2020). Net loss: US$39.2m (down 294% from profit in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.
Recent Insider Transactions • May 11Executive VP & COO recently bought €99k worth of stockOn the 7th of May, Tausif Butt bought around 11k shares on-market at roughly €9.10 per share. This was the largest purchase by an insider in the last 3 months. This was Tausif's only on-market trade for the last 12 months.
Reported Earnings • May 02First quarter 2021 earnings released: US$0.43 loss per share (vs US$0.35 loss in 1Q 2020)The company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: US$10.4m (up 72% from 1Q 2020). Net loss: US$29.7m (loss widened 37% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has increased by 59% per year, which means it is well ahead of earnings.
Recent Insider Transactions • Mar 13Director recently sold €1.5m worth of stockOn the 5th of March, Geoffrey Parker sold around 32k shares on-market at roughly €47.52 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €4.8m more than they bought in the last 12 months.
Reported Earnings • Mar 02Full year 2020 earnings released: US$0.84 loss per share (vs US$0.97 loss in FY 2019)The company reported a solid full year result with improved revenues and control over costs, although losses were not reduced. Full year 2020 results: Revenue: US$64.9m (up 80% from FY 2019). Net loss: US$55.4m (flat on FY 2019). Over the last 3 years on average, earnings per share has fallen by 65% per year but the company’s share price has increased by 86% per year, which means it is well ahead of earnings.
Analyst Estimate Surprise Post Earnings • Mar 02Revenue misses expectationsRevenue missed analyst estimates by 5.6%. Over the next year, revenue is expected to shrink by 19% compared to a 55% growth forecast for the Biotechs industry in Germany.
Is New 90 Day High Low • Feb 06New 90-day high: €54.18The company is up 20% from its price of €45.32 on 06 November 2020. The German market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €86.28 per share.
Recent Insider Transactions • Feb 05Independent Director recently sold €1.0m worth of stockOn the 2nd of February, Thomas Edwards sold around 20k shares on-market at roughly €50.67 per share. In the last 3 months, they made an even bigger sale worth €1.3m. Insiders have been net sellers, collectively disposing of €3.3m more than they bought in the last 12 months.
Recent Insider Transactions • Dec 30Independent Director recently sold €1.3m worth of stockOn the 28th of December, Thomas Edwards sold around 25k shares on-market at roughly €50.19 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €2.3m more than they bought in the last 12 months.
Is New 90 Day High Low • Dec 15New 90-day high: €49.12The company is up 12% from its price of €43.92 on 16 September 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €76.07 per share.
Is New 90 Day High Low • Dec 10New 90-day high: €47.85The company is up 12% from its price of €42.71 on 03 September 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €70.28 per share.
Is New 90 Day High Low • Nov 20New 90-day high: €47.06The company is up 4.0% from its price of €45.15 on 21 August 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €68.44 per share.
Reported Earnings • Nov 11Third quarter 2020 earnings released: US$0.35 loss per shareThe company reported a poor third quarter result with increased losses and weaker revenues and control over expenses. Third quarter 2020 results: Revenue: US$5.09m (down 52% from 3Q 2019). Net loss: US$24.1m (loss widened 87% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has increased by 96% per year, which means it is well ahead of earnings.
Analyst Estimate Surprise Post Earnings • Nov 11Revenue misses expectationsRevenue missed analyst estimates by 53%. Over the next year, revenue is expected to shrink by 6.9% compared to a 309% growth forecast for the Biotechs industry in Germany.
공시 • Oct 29ChemoCentryx, Inc. Announces Positive Topline Results of Phase II Aurora Clinical Trial of Avacopan in the Treatment of Hidradenitis Suppurativa (HS)ChemoCentryx, Inc. announced positive topline data from the company’s AURORA randomized, double-blind, placebo-controlled, multi-center Phase II clinical trial of avacopan for the treatment of the chronic disabling skin disease Hidradenitis Suppurativa (HS). Avacopan is a first-in-class, orally-administered selective inhibitor of the complement C5a receptor. The Phase II AURORA clinical trial randomized 398 patients to one of three treatment arms. The study population included patients with moderate HS (Hurley Stage II) or severe HS (Hurley Stage III), which were stratified evenly across the treatment groups. The primary endpoint of the proportion of all patients (both moderate Hurley Stage II plus severe Hurley Stage III) achieving Hidradenitis Suppurativa Clinical Response (HiSCR), as assessed 10 mg twice-daily (BID) and 30 mg BID dosing regimens of avacopan against placebo after 12 weeks of treatment in the combined study population, was not achieved with statistical significance at either dose level, although a numerical improvement was noted at the 30mg BID dose. Importantly, avacopan 30mg BID demonstrated a statistically significant higher response than placebo in the pre-specified population of Hurley Stage III (severe) HS patients in the study. The Company plans to advance avacopan into Phase III development for the treatment of severe HS. A consistency of effect with avacopan was noted in Hurley Stage III patients across every secondary endpoint assessed to date. Favorable reductions for avacopan were observed in International HS Severity Score (IHS4), as well as reduction in AN (abscesses and inflammatory nodules), draining fistula, and abscess count at week 12 (all % change from baseline to week 12), relative to placebo. Avacopan demonstrated a favorable safety profile. Treatment emergent adverse events (TEAEs) of all types were observed to be fewer in the avacopan groups (48.5%) than with placebo (55%). The majority of TEAEs were related to underlying HS and were mild to moderate. Serious TEAEs were observed in 2.3% of placebo patients vs. 1.5% on avacopan.
공시 • Sep 18ChemoCentryx, Inc. Announces FDA Acceptance of the Avacopan New Drug Application for the Treatment of ANCA-Associated VasculitisChemoCentryx, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for avacopan, an orally-administered selective complement 5a receptor inhibitor, for the treatment of ANCA-Associated Vasculitis and has set July 7, 2021 as the Prescription Drug User Fee Act (PDUFA) goal date for the avacopan NDA. Avacopan is a first-in-class, orally administered therapy that employs a novel, highly targeted mode of action in the treatment of ANCA-associated vasculitis. In its NDA acceptance letter, the FDA also indicated that it may, but has not yet determined whether to hold an advisory committee meeting to discuss the application per guidelines for new molecular entities. The NDA included data from the global, Phase III ADVOCATE trial, which demonstrated statistical superiority in sustaining remission at 52 weeks in the avacopan group compared to the prednisone group. In the trial, the avacopan group also showed significantly lower glucocorticoid toxicity, greater improvement in kidney function and greater improvement in health-related quality of life measures compared to the prednisone group. Finally, avacopan demonstrated favorable safety results, with fewer patients having serious adverse events in the avacopan group than in the prednisone group. ADVOCATE and ANCA-Associated Vasculitis: The ADVOCATE trial of avacopan was a global, randomized, double-blind, active-controlled, double-dummy Phase III trial of 331 patients with ANCA-associated vasculitis in 20 countries. Eligible study subjects were randomized to receive avacopan plus either rituximab or cyclophosphamide (followed by azathioprine/mycophenolate) or prednisone plus either rituximab or cyclophosphamide (followed by azathioprine/mycophenolate). ANCA-associated vasculitis is a systemic disease in which over-activation of the complement pathway further activates neutrophils, leading to inflammation and destruction of small blood vessels. This results in organ damage and failure, with the kidney as the major target, and is fatal if not treated. Currently, treatment for ANCA-associated vasculitis consists of courses of non-specific immuno-suppressants (cyclophosphamide or rituximab), combined with the administration of daily glucocorticoids (steroids) for prolonged periods of time, which can be associated with significant clinical risk including death from infection. Avacopan is a first-in-class, orally-administered small molecule that employs a novel, highly targeted mode of action in the treatment of ANCA-associated vasculitis and other complement-driven autoimmune and inflammatory diseases. By precisely blocking the receptor (the C5aR) for the pro-inflammatory complement system fragment known as C5a on destructive inflammatory cells such as blood neutrophils, avacopan arrests the ability of those cells to do damage in response to C5a activation, which is known to be the driver of ANCA-associated vasculitis. Current therapies for ANCA-associated vasculitis and other related illnesses typically include broad immunosuppression with daily doses of glucocorticoids (steroids) such as prednisone or methylprednisone, which can cause significant illness and even death. Avacopan therapy was designed to prevent these outcomes. Moreover, avacopan’s selective inhibition of only the C5aR leaves the beneficial C5a pathway through the C5L2 receptor functioning normally. ChemoCentryx is also developing avacopan for the treatment of patients with C3 glomerulopathy (C3G) and hidradenitis suppurativa (HS). The U.S. Food and Drug Administration has granted avacopan orphan drug designation for ANCA-associated vasculitis and C3G. The European Commission has granted orphan medicinal product designation for avacopan for the treatment of two forms of ANCA-associated vasculitis: microscopic polyangiitis and granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis), as well as for C3G. ChemoCentryx is responsible for the discovery and development of avacopan and owns and retains the commercial rights to the drug in the United States. ChemoCentryx's Kidney Health Alliance with Vifor Pharma provides Vifor Pharma with exclusive rights to commercialize avacopan in markets outside of the U.S.
공시 • Aug 04ChemoCentryx, Inc. to Report Q2, 2020 Results on Aug 10, 2020ChemoCentryx, Inc. announced that they will report Q2, 2020 results at 5:00 PM, Eastern Standard Time on Aug 10, 2020
공시 • Jul 03ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from Russell Microcap IndexChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from Russell Microcap Index